Jeffrey A. Lieberman

96.6k total citations · 19 hit papers
602 papers, 54.1k citations indexed

About

Jeffrey A. Lieberman is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Cognitive Neuroscience. According to data from OpenAlex, Jeffrey A. Lieberman has authored 602 papers receiving a total of 54.1k indexed citations (citations by other indexed papers that have themselves been cited), including 365 papers in Psychiatry and Mental health, 116 papers in Cellular and Molecular Neuroscience and 100 papers in Cognitive Neuroscience. Recurrent topics in Jeffrey A. Lieberman's work include Schizophrenia research and treatment (342 papers), Bipolar Disorder and Treatment (89 papers) and Mental Health and Psychiatry (73 papers). Jeffrey A. Lieberman is often cited by papers focused on Schizophrenia research and treatment (342 papers), Bipolar Disorder and Treatment (89 papers) and Mental Health and Psychiatry (73 papers). Jeffrey A. Lieberman collaborates with scholars based in United States, Canada and Germany. Jeffrey A. Lieberman's co-authors include Joseph P. McEvoy, T. Scott Stroup, Diana O. Perkins, Sonia M. Davis, Robert A. Rosenheck, Richard S.E. Keefe, Marvin S. Swartz, John Hsiao, John M. Kane and Robert M. Bilder and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Jeffrey A. Lieberman

591 papers receiving 51.7k citations

Hit Papers

Effectiveness of Antipsychotic Drugs in Patients with... 1992 2026 2003 2014 2005 1999 2005 2005 2006 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
    2005 4.2k citations Jeffrey A. Lieberman, T. Scott Stroup et al. profile →
  2. Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder
    1999 1.0k citations Brian Sheitman, Miranda Chakos et al. profile →
  3. Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis
    2005 962 citations Diana O. Perkins, Jeffrey A. Lieberman et al. American Journal of Psychiatry profile →
  4. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
    2005 897 citations Joseph P. McEvoy, Donald Goff et al. profile →
  5. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
    2006 760 citations T. Scott Stroup, Jeffrey A. Lieberman et al. profile →
  6. Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States
    1993 725 citations Jeffrey A. Lieberman et al. profile →
  7. Neuropsychology of First-Episode Schizophrenia: Initial Characterization and Clinical Correlates
    2000 722 citations Jeffrey A. Lieberman et al. American Journal of Psychiatry profile →
  8. Duration of psychosis and outcome in first-episode schizophrenia
    1992 663 citations Jeffrey A. Lieberman et al. American Journal of Psychiatry profile →
  9. Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis
    2005 593 citations Jeffrey A. Lieberman profile →
  10. Brain volume in first-episode schizophrenia
    2006 592 citations Robert M. Hamer, Jeffrey A. Lieberman et al. profile →
  11. Catching Up on Schizophrenia
    2000 581 citations Jeffrey A. Lieberman et al. profile →
  12. Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment
    2006 557 citations Joseph P. McEvoy, Jeffrey A. Lieberman et al. American Journal of Psychiatry profile →
  13. A National Study of Violent Behavior in Persons With Schizophrenia
    2006 539 citations T. Scott Stroup, Joseph P. McEvoy et al. profile →
  14. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development
    2003 512 citations T. Scott Stroup, Joseph P. McEvoy et al. Schizophrenia Bulletin profile →
  15. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
    2012 426 citations Jeffrey A. Lieberman et al. profile →
  16. Imaging Patients with Psychosis and a Mouse Model Establishes a Spreading Pattern of Hippocampal Dysfunction and Implicates Glutamate as a Driver
    2013 400 citations Cheryl M. Corcoran, Jeffrey A. Lieberman et al. profile →
  17. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
    2012 297 citations Jeffrey A. Lieberman et al. profile →
  18. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention
    2018 262 citations Jeffrey A. Lieberman, Ragy R. Girgis et al. Molecular Psychiatry profile →
  19. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
    2021 216 citations Jeffrey A. Lieberman et al. profile →

Peers

Jeffrey A. Lieberman
John M. Kane United States
Ming T. Tsuang United States
Nancy C. Andreasen United States
Philip McGuire United Kingdom
Jim van Os Netherlands
René S. Kahn Netherlands
Matcheri S. Keshavan United States
Herbert Y. Meltzer United States
Shitij Kapur Canada
Richard S.E. Keefe United States
John M. Kane United States
Jeffrey A. Lieberman
Citations per year, relative to Jeffrey A. Lieberman Jeffrey A. Lieberman (= 1×) peers John M. Kane

Countries citing papers authored by Jeffrey A. Lieberman

Since Specialization
Citations

This map shows the geographic impact of Jeffrey A. Lieberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Lieberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Lieberman more than expected).

Fields of papers citing papers by Jeffrey A. Lieberman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Lieberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Lieberman. The network helps show where Jeffrey A. Lieberman may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Lieberman

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Lieberman. A scholar is included among the top collaborators of Jeffrey A. Lieberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Lieberman. Jeffrey A. Lieberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zoghbi, Anthony W., Jeffrey A. Lieberman, & Ragy R. Girgis. (2022). The neurobiology of duration of untreated psychosis: a comprehensive review. Molecular Psychiatry. 28(1). 168–190. 18 indexed citations
2.
Zoghbi, Anthony W., Ryan S. Dhindsa, Terry E. Goldberg, et al.. (2021). High-impact rare genetic variants in severe schizophrenia. Proceedings of the National Academy of Sciences. 118(51). 33 indexed citations
3.
4.
Girardin, François, Antoine Poncet, Arnaud Perrier, et al.. (2018). Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. The Pharmacogenomics Journal. 19(2). 211–218. 29 indexed citations
5.
Abbas, Atheir I. & Jeffrey A. Lieberman. (2015). Pharmacological Treatments for Schizophrenia. Oxford University Press eBooks. 4 indexed citations
6.
Colibazzi, Tiziano, Bruce E. Wexler, Ravi Bansal, et al.. (2013). Anatomical Abnormalities in Gray and White Matter of the Cortical Surface in Persons with Schizophrenia. PLoS ONE. 8(2). e55783–e55783. 20 indexed citations
7.
Hirata, Yuko, Clement C. Zai, Renan P. Souza, et al.. (2012). Association study of GRIK1 gene polymorphisms in schizophrenia: case–control and family‐based studies. Human Psychopharmacology Clinical and Experimental. 27(4). 345–351. 14 indexed citations
8.
Marx, Brian P., Richard S.E. Keefe, Robert W. Buchanan, et al.. (2009). Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology. 34(8). 1885–1903. 160 indexed citations
9.
Lyon, Gholson J., Anissa Abi‐Dargham, Holly Moore, et al.. (2009). Presynaptic Regulation of Dopamine Transmission in Schizophrenia. Schizophrenia Bulletin. 37(1). 108–117. 51 indexed citations
10.
Lieberman, Jeffrey A., G.D. Tollefson, A. I. Green, et al.. (2009). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)). American Journal of Psychiatry. 166(8). 12 indexed citations
11.
Lieberman, Jeffrey A., Robert E. Drake, Lloyd I. Sederer, et al.. (2008). Science and Recovery in Schizophrenia. Psychiatric Services. 59(5). 487–496. 112 indexed citations
12.
Müller, Daniel J., Tim Klempan, Vincenzo De Luca, et al.. (2005). The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neuroscience Letters. 379(2). 81–89. 77 indexed citations
13.
Czobor, Pál, Jan Volavka, Brian Sheitman, et al.. (2002). Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association. Journal of Clinical Psychopharmacology. 22(3). 244–251. 147 indexed citations
14.
Basile, Vincenzo S., Mario Masellis, Roger S. McIntyre, et al.. (2001). Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.. PubMed. 62 Suppl 23. 45–66. 170 indexed citations
15.
Lieberman, Jeffrey A. & Robin Murray. (2001). Comprehensive care of schizophrenia : a textbook of clinical management. 32 indexed citations
16.
Basile, Vincenzo S., Mario Masellis, Vural Özdemir, et al.. (2000). Novel histamine H1 gene polymorphism and clozapine-induced weight gain. American Journal of Medical Genetics Part B Neuropsychiatric Genetics. 96(4). 538–539. 2 indexed citations
17.
Kay, Jerald, Allan Tasman, & Jeffrey A. Lieberman. (2000). Psychiatry : behavioral science and clinical essentials. 3 indexed citations
18.
Pincus, Harold Alan, et al.. (1999). Ethics in psychiatric research : a resource manual for human subjects protection. DigitalGeorgetown (Georgetown University Library). 32 indexed citations
19.
Tasman, Allan, et al.. (1998). Pocket companion to accompany psychiatry. 1 indexed citations
20.
Lieberman, Jeffrey A., et al.. (1994). The moral imperatives of medical research in human subjects.. PubMed. 5(1). 40–2. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John M. Kane Breakdown of academic impact, for papers by Ming T. Tsuang Breakdown of academic impact, for papers by Nancy C. Andreasen Breakdown of academic impact, for papers by Philip McGuire Breakdown of academic impact, for papers by Jim van Os Breakdown of academic impact, for papers by René S. Kahn Breakdown of academic impact, for papers by Matcheri S. Keshavan Breakdown of academic impact, for papers by Herbert Y. Meltzer Breakdown of academic impact, for papers by Shitij Kapur Breakdown of academic impact, for papers by Richard S.E. Keefe
Rankless by CCL
2026